Xylovin 0.01%
Various etiologies, such as rhinosinusitis and allergic or non-allergic rhinitis, induce nasal congestion, resulting in congestion of the venous sinusoids lining the nasal mucosa. Activation of -adrenergic receptors causes vasoconstriction of nasal mucosal blood vessels and restoration of nasal airflow. 1A- and 2B-adrenoceptors, which are the most abundantly expressed in the human nasal mucosa, may have the most essential function in vasoconstriction of the human nasal mucosa. Xylometazoline is a more selective 2B-adrenoceptor agonist, having affinity for 1A-, 2A-, 2C-, 1B-, and 1D-adrenoceptors.Xylometazoline reduces nasal resistance during inspiration and expiration while increasing nasal airflow volume. Xylometazoline showed a significantly quicker beginning of effect than oxymetazoline, another imidazoline nasal decongestant, although having a similar duration of action. Subjects with nasal congestion reported alleviation from earache and sore throat in addition to nasal decongestion in one study:It is thought that oxymetazoline mediates this effect by inducing vasoconstriction of the nasal mucosa, which contains the venous sinuses. Nasal decongestion permits breathing via the nose, which relieves sore throat produced by mouth breathing, which dries and irritates the throat.
Various etiologies, such as rhinosinusitis and allergic or non-allergic rhinitis, induce nasal congestion, resulting in congestion of the venous sinusoids lining the nasal mucosa. Activation of -adrenergic receptors causes vasoconstriction of nasal mucosal blood vessels and restoration of nasal airflow. 1A- and 2B-adrenoceptors, which are the most abundantly expressed in the human nasal mucosa, may have the most essential function in vasoconstriction of the human nasal mucosa. Xylometazoline is a more selective 2B-adrenoceptor agonist, having affinity for 1A-, 2A-, 2C-, 1B-, and 1D-adrenoceptors.Xylometazoline reduces nasal resistance during inspiration and expiration while increasing nasal airflow volume. Xylometazoline showed a significantly quicker beginning of effect than oxymetazoline, another imidazoline nasal decongestant, although having a similar duration of action. Subjects with nasal congestion reported alleviation from earache and sore throat in addition to nasal decongestion in one study:It is thought that oxymetazoline mediates this effect by inducing vasoconstriction of the nasal mucosa, which contains the venous sinuses. Nasal decongestion permits breathing via the nose, which relieves sore throat produced by mouth breathing, which dries and irritates the throat.
Various etiologies, such as rhinosinusitis and allergic or non-allergic rhinitis, induce nasal congestion, resulting in congestion of the venous sinusoids lining the nasal mucosa. Activation of -adrenergic receptors causes vasoconstriction of nasal mucosal blood vessels and restoration of nasal airflow. 1A- and 2B-adrenoceptors, which are the most abundantly expressed in the human nasal mucosa, may have the most essential function in vasoconstriction of the human nasal mucosa. Xylometazoline is a more selective 2B-adrenoceptor agonist, having affinity for 1A-, 2A-, 2C-, 1B-, and 1D-adrenoceptors.Xylometazoline reduces nasal resistance during inspiration and expiration while increasing nasal airflow volume. Xylometazoline showed a significantly quicker beginning of effect than oxymetazoline, another imidazoline nasal decongestant, although having a similar duration of action. Subjects with nasal congestion reported alleviation from earache and sore throat in addition to nasal decongestion in one study:It is thought that oxymetazoline mediates this effect by inducing vasoconstriction of the nasal mucosa, which contains the venous sinuses. Nasal decongestion permits breathing via the nose, which relieves sore throat produced by mouth breathing, which dries and irritates the throat.
Dosage & Administration
Adults: Xylometazoline 0.1%: 2 or 3 drops in each nostril two to three times daily. Xylometazoline 0.1% should not be used for children under the age of 12 years.
Children 6 to 12 years of age: Xylometazoline 0.05%: 2 or 3 drops in each nostril two or three times daily.
Children less than 6 years of age: Xylometazoline 0.05%: 1 drop in each nostril two or three times daily.
Infants less than 3 months: Not to be used in infants less than 3 months.
Contraindications
Xylometazoline nasal drops are not recommended for individuals who have had a transsphenoidal hypophysectomy or surgery that exposed the dura mater. It is also not recommended for people who are allergic to Xylometazoline. To avoid cross-infection, each Xylometazoline nasal drop should only be used by one individual. Patients should not use decongestants for more than seven days in a row.
Side Effects
The following adverse effects have been reported on occasion:
The sense of a burning sensation in the nose and throat
Irritation at the site
Nausea and nasal mucosal dryness
Pregnancy & Lactation
C is the pregnancy category. Xylometazoline should not be used when pregnant. The use of Otrivin while nursing should be done exclusively under the supervision of a doctor.
Precautions & Warnings
Adults should not use Xylometazoline Hydrochloride nasal drops (0.1 percent) on children under the age of 12. Drops should not be used for an extended period of time in situations of chronic rhinitis. Long-term usage of the drops may result in rebound congestion and drug-induced rhinitis.
Therapeutic Class
Nasal Anti-histamine preparations
Storage Conditions
Keep out of direct sunlight. For hygienic concerns, do not use the bottle more than 28 days after it has been opened.